证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2015-001 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及 | 中信建投证券股份有限公司 杨扬 | | | 人员姓名 | | | | 时间 | 2015 年 3 月 6 | 日上午 10 点半 | | 地点 | 公司会议室 | | | 上市公司接待人 | 侯占军、黄志宇、董国明 | | | 员姓名 | | | | 投资者关系活动 | | 公司指出本次访谈内容不涉及目前正在筹划的重大事项，访 | | 主要内容介绍 | | 谈内容限定于公司公 ...

证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2016-006 | --- | --- | --- | --- | |-----------------------------|-----------------------------|----------------------------------------------|--------------------------------------------------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 类别 | | □业绩说明会 □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他 | | | 参与单位名称及 | 东兴证券股份有限公司 虞瑞捷 | | | | 人员姓名 时间 | 2016 年 7 月 13 | 日下午 15:30 | | | 地点 | 神舟大厦会议室 | | | | 上市公司接待人 | | | 中关村科技董事长兼总裁侯占军；董事会秘书黄志宇； | | 员姓名 | | 华素制药董事兼总 ...

证券代码： 000931 证券简称：中关村 参 与 单 位 名 润晖投资李诗晗；融通基金管理有限公司姜建华；华融证券股份有限公 称 及 人 员 姓 司徐易、许之捷；北京正弘投资管理有限公司周情、陈录；北京中财龙 名 马投资管理有限公司章健敏。 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2016-005 | --- | --- | --- | |----------------|--------------------------------------|-------| | | | | | 投 资 者 关 系 | √ 特定对象调研 □分析师会议 □媒体采访 | | | 活动类别 | □业绩说明会 □新闻发布会 □路演活动 | | | | □ 现场参观 | | | --- | --- | |--------------------------------------|--------------------------------------------------| | 时间 | 2016 年 6 月 3 日上午 9:30 | | 地点 | 神舟大厦会议室 | | 上 市 公 司 接 ...

证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2016-003 | --- | --- | --- | |--------------|-------------------------|----------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | □其他 | | 参与单位名称 | | 申万菱信基金管理有限公司赵世光、杨扬 | | 及人员姓名 | | | | 时间 | 2016 年 5 月 18 | 日下午 3 点 | | 地点 | 神舟大厦会议室 | | | 上市公司接待 | | 中关村科技董事长兼总裁侯占军；董事会秘书黄志宇； | | 人员姓名 | | 华素制药董事兼总经理、多多药业董事长董国明 | | 投资者关系活 | | 公司指出本次访谈内容仅限定于公司公开披露信息，凡涉及 | | ...

Financial Performance - In 2015, the company achieved a revenue of 1.078 billion yuan, a decrease of 64.47% compared to the previous year, with a net profit of 153 million yuan, of which 151 million yuan was attributable to the parent company, an increase of 13.7 million yuan year-on-year [3] - In Q1 2016, the company reported a revenue of 260 million yuan, a growth of 91.94% year-on-year, while the net profit attributable to the parent company was -16 million yuan, an increase of 17.11% compared to the same period last year [3] - The pharmaceutical business generated a revenue of 52.989 million yuan in 2015, with a profit of 42.61 million yuan [3] Strategic Development - The company adjusted its development strategy in September 2015 to focus on the "big health industry" as its core business [4] - The company plans to expand its business scale through acquisitions, self-construction, and establishing industry merger funds [5] - The acquisition of Duoduo Pharmaceutical is expected to enhance the company's competitiveness in the pharmaceutical sector [7] Market Position and Product Development - Duoduo Pharmaceutical holds a market share of approximately 40% for its main product, Tramadol hydrochloride raw material [6] - The sales of Duoduo's Lactobacillus tablets reached an average annual growth rate of 27.4% from 2013 to 2015, with a total sales volume of about 1 billion tablets in 2015 [6] - The company aims to leverage its brand advantages to expand the market share of Duoduo's Lactobacillus tablets [6] Acquisition Impact - The acquisition of Duoduo Pharmaceutical is expected to enrich the product structure and strengthen the market position of various drug categories [7] - The combined sales network of Huasu Pharmaceutical and Duoduo Pharmaceutical will enhance regional coverage and hospital penetration [8] - The acquisition is projected to improve the company's profitability and operational efficiency [7] Research and Development - The company has established a partnership with the Military Medical Academy for drug research and development, focusing on innovative drug platforms [10] - The company has made progress in independent research and development, obtaining clinical approvals for several products [11] - The company is actively pursuing new indications for existing drugs, which are expected to have significant market potential [13] Fundraising and Financial Strategy - The company plans to raise up to 710 million yuan through a private placement of shares to repay debts and fund strategic projects [14] - The private placement will involve issuing no more than 82,847,100 new shares, with a pricing benchmark set at 90% of the average trading price over the previous 20 trading days [15]

Group 1: Company Overview and Business Structure - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. focuses on the pharmaceutical and health industry, with a strategic shift towards "big health" as its core business [11][12] - The company has two research and development centers, three production bases, and three sales teams [3][4] Group 2: Research and Development Progress - The company has obtained 12 production approvals, including various drug categories, and has made significant advancements in clinical trials and patent applications [3][4][6] - Current R&D projects include pain management drugs and anti-fungal agents, with a focus on enhancing product lines and meeting market demands [6][7][8] Group 3: Sales and Market Performance - The OTC and health product division has established a strong market presence, with over 1,000 retail outlets and hospitals engaged by the end of April 2016 [4][5] - The company’s prescription drug division has seen a revenue growth of nearly 60% year-on-year, indicating robust market performance [5] Group 4: Future Business Development Plans - The company plans to execute at least two merger and acquisition projects annually, focusing on expanding its pharmaceutical production capabilities and exploring opportunities in medical devices and healthcare services [12][13] - A new marketing strategy will be implemented to enhance sales team engagement and operational efficiency [13] Group 5: Production and Talent Development - Plans to expand production capacity include building a new production line for tablets and establishing a sterile production facility to meet regulatory requirements [14][15] - The company aims to enhance its workforce by recruiting skilled professionals and implementing an incentive program to align employee goals with corporate strategy [15] Group 6: Non-Pharmaceutical Asset Management - The company holds over 1 billion CNY in non-pharmaceutical assets, with a focus on divesting non-core assets to strengthen its pharmaceutical business [16]

证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |----------------|-------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ 其他 | （交易所投资者平台书面问询） | | 参与单位名称及 | | 广州广证恒生证券研究所有限公司 医药行业研究员 唐爱金 | | 人员姓名 | | 工银瑞信基金管理有限公司 研究部研究员 谭冬寒 | | | | 工银瑞信基金管理有限公司 研究部研究员 庞文杰 | | 时间 | 2016 年 1 月 25 | 日 下午 2 点 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事长兼总裁 侯占军 | | | 员姓名 ...

Group 1: Company Overview - Dachen Fund Management Company is one of the "old ten" fund management companies in China, with a management scale of approximately 150 billion RMB [3] - The company has established a good cooperative relationship with the Military Medical Academy and is focusing on the pharmaceutical and health industry [3] Group 2: Strategic Transformation - The company is actively implementing a future development strategy centered on specialized hospitals, elderly care, and precision medicine [3] - The focus is on oncology, ophthalmology, and rehabilitation, with plans to combine rehabilitation with elderly care services [3] Group 3: Product Development - The "Huasu Yuchuang" series of toothpaste, launched in September 2015, targets oral mucosa repair and has received positive market feedback [4][5] - Sales revenue for the health product business is expected to exceed 100 million RMB in 2016, with a focus on expanding sales channels [4][6] Group 4: Market Positioning - The toothpaste is positioned as a functional product, targeting specific consumer groups such as cancer patients and those undergoing dental procedures [7] - The company aims to establish a presence in 5,000 dental hospitals and 40,000 pharmacies over the next 2-3 years [6] Group 5: Shareholder Support - Gome Holdings increased its shareholding to 24.47% after purchasing additional shares, and is supportive of the company's business transformation [7][8] - The company plans to leverage Gome's e-commerce platform to enhance sales and channel integration [8] Group 6: Fundraising Efforts - The company received approval for a non-public offering of up to 82,847,100 shares, with a fundraising target of 71 million RMB [9][10] - The company is actively working to implement this offering to accelerate strategic transformation and reduce financial costs [10]

证券代码： 000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | --- | |-----------------------------|------------------------|--------------------------------------------------|-------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 类别 | | □业绩说明会 □新闻发布会 □路演活动 | | | | □ 现场参观 | □其他 | | | 参与单位名称及 | 华夏基金管理有限公司 | 王泽实 | | | 人员姓名 | | 东鼎国际财富投资管理有限公司胡祥德、孙毅 | | | 时间 | 2017 年 1 月 5 | 日上午 10:30 | | | 地点 | 神舟大厦会议室 | | | | 上市公司接待人 | | 中关村科技董事长兼总裁侯占军、董事会秘书黄志宇； | | | 员姓名 | 副总经理：董国明、李斌 | | | | 投资者关 ...